Dose-Dependent Antidepressant-Like Effects of Cannabidiol in Aged Rats

Hernández-Hernández, Elena; García-Fuster, M. Julia

doi:10.3389/fphar.2022.891842

Cited by 7 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Note, however, that it has an entirely different set of pharmacological actions compared to THC [7]). CBD has also demonstrated efficacy in treating affective disorders (e.g., anxiety [15][16][17][18][19][20][21], preclinical models of depression [22][23][24][25][26][27][28]) and been reported, albeit inconsistently [29], to increase blood concentrations of anandamide [30,31], an endogenous cannabinoid that appears to contribute to the 'runner's high' (i.e., 'pleasant' feeling sometimes experienced during endurance exercise) [32].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Cannabidiol on Subjective Responses to Endurance Exercise: A Randomised Controlled Trial

McCartney,

Irwin,

Bawa

et al. 2024

Sports Med - Open

View full text Add to dashboard Cite

Background Exercise is known to improve health. However, it can be unpleasant, often inducing negative feelings, or ‘affect’. Cannabidiol (CBD), a non-intoxicating constituent of the cannabis plant, has been reported to enhance the subjective experience of exercise; specifically, in trained individuals performing fixed-intensity endurance activity. Here, we investigated the effects of CBD on subjective responses to exercise under more ecologically valid conditions; namely, in recreationally active individuals performing self-paced endurance activity. Methods A randomised, double-blind, placebo-controlled, crossover trial was conducted at Griffith University between July 17 and August 28, 2023. Griffith University students studying sports nutrition were invited to take part, with eligible volunteers ≥ 18 years of age and able to perform endurance exercise. Participants ingested placebo or 150 mg CBD in two soft-gel capsules 90 min before completing a self-paced 25-lap (10 km) run around an outdoor athletics track (400 m, synthetic). The primary outcomes were affective valence during exercise, assessed on completion of laps 6, 12, 18 and 24 using the ‘Feelings Scale’, and positive and negative affect, assessed at baseline, pre-run and post-run using the ‘Positive and Negative Affect Schedule’. Exercise enjoyment, motivation and self-efficacy, the core features of the ‘runner’s high’ (i.e., euphoria, pain, anxiety, sedation), perceived exertion and run time were also assessed. Results Fifty-two participants were randomised and 51 were included in the final sample (n = 22 female; 22 [21–25] years). Exercise induced negative affect (i.e., at the time of undertaking) and increased pain. CBD did not counteract either response. In fact, CBD had no significant effects on any of the outcomes measured. In contrast, exercise, once completed, increased positive affect, and decreased negative affect and anxiety. Conclusions CBD (150 mg, oral) does not appear to enhance the subjective experience of self-paced endurance exercise in recreationally active individuals. Nor, however, does it appear to compromise it. These findings suggest that CBD use is safe under exercise conditions and unlikely to impede physical activity participation. Our study also reaffirms the powerful mood-enhancing effects of exercise. Trial Registration Registered with the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) on May 31, 2023 (Trial ID: ACTRN12623000593639).

show abstract

Section: Introductionmentioning

confidence: 99%

The Effect of Cannabidiol on Subjective Responses to Endurance Exercise: A Randomised Controlled Trial

McCartney,

Irwin,

Bawa

et al. 2024

Sports Med - Open

View full text Add to dashboard Cite

show abstract

Alzheimer’s disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging

Liu

2024

Mol Biol Rep

View full text Add to dashboard Cite

Cannabinoids and healthy ageing: the potential for extending healthspan and lifespan in preclinical models with an emphasis on Caenorhabditis elegans

Wang,

Arnold

2024

GeroScience

View full text Add to dashboard Cite

There is a significant global upsurge in the number and proportion of older persons in the population. With this comes an increasing prevalence of age-related conditions which pose a major challenge to healthcare systems. The development of anti-ageing treatments may help meet this challenge by targeting the ageing process which is a common denominator to many health problems. Cannabis-like compounds (cannabinoids) are reported to improve quality of life and general well-being in human trials, and there is increasing preclinical research highlighting that they have anti-ageing activity. Moreover, preclinical evidence suggests that endogenous cannabinoids regulate ageing processes. Here, we review the anti-ageing effects of the cannabinoids in various model systems, including the most extensively studied nematode model, Caenorhabditis elegans. These studies highlight that the cannabinoids lengthen healthspan and lifespan, with emerging evidence that they may also hinder the development of cellular senescence. The non-psychoactive cannabinoid cannabidiol (CBD) shows particular promise, with mechanistic studies demonstrating it may work through autophagy induction and activation of antioxidative systems. Furthermore, CBD improves healthspan parameters such as diminishing age-related behavioural dysfunction in models of both healthy and accelerated ageing. Translation into mammalian systems provides an important next step. Moreover, looking beyond CBD, future studies could probe the multitude of other cannabis constituents for their anti-ageing activity.

show abstract

Dose-Dependent Antidepressant-Like Effects of Cannabidiol in Aged Rats

Cited by 7 publications

References 57 publications

The Effect of Cannabidiol on Subjective Responses to Endurance Exercise: A Randomised Controlled Trial

The Effect of Cannabidiol on Subjective Responses to Endurance Exercise: A Randomised Controlled Trial

Alzheimer’s disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging

Cannabinoids and healthy ageing: the potential for extending healthspan and lifespan in preclinical models with an emphasis on Caenorhabditis elegans

Contact Info

Product

Resources

About